To develop a reliable patient-reported outcome (PRO) measure on quality of life (QOL) in lipoprotein lipase deficiency (LPLD) through patient assessment of the existing European Organization for Research and Treatment of Cancer (EORTC) questionnaires (QLQ-C30 and QLQ-PAN26) and a new questionnaire on disease burden devised by clinicians with experience in treating the condition.
Pain

C30 73%
Uncomfortable in certain positions PAN26 73%
Pain interfering with daily activities C30 64%
Pain occurring during the night PAN26 64%
Digestive/ diet
Restriction in type of food PAN26 100%
Restriction in amounts of food PAN26 73% Indigestion PAN26 64%
Lacked appetite C30 55%
Bloating in abdomen PAN26 55%
Fatigue/ Insomnia
Were tired C30 73%
Need to rest C30 64%
Felt weak C30 55%
Trouble with sleeping C30 64%
Emotional Functioning
Worried about your health in the future PAN 26 73%
Worried about your weight being too low PAN 26 64% Worried C30 55%
Role/ Social Functioning
Limited in work / other daily activities C30 64%
Limited in planning activities PAN26 64%
Condition/treatment interfered with social activities C30 73%
Satisfaction with HCPs
Received adequate support PAN26 91%
Given adequate information about condition/treatment PAN26 91%
Vary the amount of fat eaten without getting symptoms To develop a reliable patient-reported outcome (PRO) measure on quality of life (QOL) in lipoprotein lipase deficiency (LPLD) through patient assessment of the existing European Organization for Research and Treatment of Cancer (EORTC) questionnaires (QLQ-C30 and QLQ-PAN26) and a new questionnaire on disease burden devised by clinicians with experience in treating the condition.
■ Introduction: There is limited data on the impact of LPLD on patients´ QOL
• LPLD, an ultra-orphan (1-2 per 1,000,000) autosomal recessive genetic disorder, is caused by muta tions of the gene which encodes for lipoprotein lipase (LPL).
• It is characterized by severe chylomicronemia and consequently, severe hypertriglyceridemia (>2000 mg/dL or >22.6 mmol/L).
(1)
• Clinical manifestations of LPLD can be heterogeneous -perhaps due to the large number of different mutations (>200), which have so far been found to cause LPLD.
• At all ages, the most common clinical manifestation is recurrent severe abdominal pain. Other associated symptoms -although not present in all patients -are: -Eruptive xanthoma -Hepatosplenomegaly -Lipemia retinalis -Dementia, depression and memory loss -Cardiopulmonary symptoms • The most severe, sometimes life-threatening complication of LPLD is recurrent episodes of acute pancreatitis, which can lead to pancreatic insufficiency and diabetes.
• Treatment of LPLD has been limited to maintaining an ultra-low-fat diet, though this is difficult to sustain and often ineffective. Lipid-lowering drugs show only limited efficacy based on anecdotal evidence.
Development of a PRO measure in LPLD is a post-approval commitment of alipogene tiparvovec
• Alipogene tiparvovec (3) is the first approved gene therapy in the Western world, developed for the treatment of LPLD.
• Regulators requested development of a reliable measure of QOL in LPLD as part of the risk management plan for alipogene tiparvovec, and for the measure to be included in the GENIALL Registry, a 15-year post-approval safety study on the natural history of LPLD as well as the long term safety and efficacy of gene therapy (Fig. 1 ).
• Two existing EORTC questionnaires were considered to have sufficient relevance to LPLD: -QLQ-C30: a widely used quality of life measure originally developed to assess quality of life in cancer patients -QLQ-PAN26: an add-on module to the QLQ-C30 assessing concerns and symptoms of pancreatic cancer patients • Both QLQs have been successfully tested among patients with chronic pancreatitis (5) and recurrent acute pancreatitis, (6) diseases with clinical features overlapping with LPLD.
• A new questionnaire of disease burden has been created by clinicians with experience in treating LPLD to supplement the existing, non-LPLD-specific measures, but has never been systemically assessed by LPLD patients.
■ Results: 46% of the items of the EORTC scales were considered relevant by the majority of participants
• The participants had a mean age of 39 years (range: 19-56) and included 6 males and 5 females. • In the EORTC QLQ-C30 12 of the 30 items (40%) and in the PAN-26 14 of the 26 items (54%) were considered relevant by the majority (≥6) of LPLD respondents.
• Key domains identified aligned closely with the well-known manifestations of LPLD. (Figure 2 ; Table 1) ■ Methods: Quantitative assessment and in-depth interviews
• Participants: 11 genetically confirmed LPLD patients from Canada (N=2), France (N=3), Germany (N=1), Italy (N=1), The Netherlands (N=1), and The United Kingdom (N=3).
• IRB approval was obtained and all participants provided informed consent.
• Procedure:
-Local language versions were created through standard translation procedures for PRO measures -Participants individually assessed each item of the three questionnaires for relevance (yes/no), and importance (1=not at all; 4=very much) -Patients' ratings were discussed during an in-depth, face-to-face cognitive debriefing interview • Incremental changes were made to the LPLD questionnaire based on participant feedback from the first 7 participants, and the adapted version was tested in another 4 LPLD patients. Note: General QOL questions and questions about troubles due to side-effects of treatment were also considered relevant, but are not presented here.
* Number of items per domain considered relevant by majority of LPLD patients or not relevant. ** Importance reported on a 1-4 scale from not at all important to very important.
* Added for the second round of interviews (N=4); Only respondents who considered item relevant rated importance for the item.
• The first round of interviews resulted in several adjustments to the draft LPLDspecific QOL questionnaire: -Wording changes to improve respondents' understanding -Elimination of item for joint pain due to lack of relevance -Addition of items for › Being restricted in ability to drink alcohol › Needing to rely on painkillers
• After incorporating feedback from initial participants, all items considered relevant were also considered important by the patients. (Figure 3) • Key LPLD-relevant items identified in the newly developed questionnaire are: -Diet focused items, including control of the disease through strict low fat diet, restriction in alcohol and days without eating -Worrying about attacks of abdominal pain -Restrictions in social activities and long term projects
• Dyspnea and eruptive xanthoma were seen as relevant by less than half of participants, potentially due to the known low prevalence in the LPLD population.
• All items were well understood by the patients interviewed.
Conclusions:
• This evaluation represents a significant and positive step towards a validated PRO for LPLD.
• Six domains relevant to QOL among LPLD patients have been identified in the existing EORTC C30 and PAN26 questionnaires.
• The items in the new LPLD disease-specific QOL questionnaire are considered relevant, important, and are well understood by patients.
• The revised measure will be psychometrically validated in a broader sample of LPLD patients within the GENIALL Registry. ■ Results: Most of the newly developed questions were considered relevant by the majority of participants 
